The role of phenformin and ethyloestrenol or stanozolol in the treatment of decreased fibrinolytic states. (Cutaneous vasculitis, Raynaud's disease, Behcet's syndrome, recurrent deep vein thrombosis and post myocardial infarction).
D000284:Administration, Oral; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced; D000925:Anticoagulants / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000097:blood / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005032:Ethylestrenol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood; D010629:Phenformin / Q000008:administration & dosage / Q000627:therapeutic use*; D010689:Phlebitis / Q000188:drug therapy; D011928:Raynaud Disease / Q000188:drug therapy; D012871:Skin Diseases / Q000097:blood / Q000188:drug therapy; D013197:Stanozolol / Q000627:therapeutic use*; D013923:Thromboembolism / Q000188:drug therapy; D013924:Thrombophlebitis / Q000188:drug therapy; D014647:Varicose Ulcer / Q000188:drug therapy
D000925:Anticoagulants; D013197:Stanozolol; D005032:Ethylestrenol; D010629:Phenformin